Bagsvrd, Denmark, 3 October 2022 Novo Nordisk today announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes.
The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300) in 1,085 insulin-nave people with type 2 diabetes in a clinical practice setting including fewer trial visits compared to the other ONWARDS phase 3a trials. Once-weekly insulin icodec was used in combination with a dosing guide app to guide titration.
The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with insulin icodec compared with once-daily basal insulin analogues. From an overall baseline HbA1c of 8.9%, once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of 1.68%-points compared with 1.31%-points for the once-daily basal insulins (estimated treatment difference: 0.38%-points).
In the trial, there was no statistically significant difference in estimated rates of severe or clinically significant hypoglycaemia (blood glucose below 3 mmol/L) with 0.19 events per patient-year exposed to once-weekly insulin icodec and 0.14 events per patient-year exposed to the once-daily basal insulins. In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile.
We are very pleased to share the positive results from the ONWARDS 5 trial. These results include real-world elements and a dosing guide app, which help us better understand how insulin icodec can make a difference for patients in a clinical practice setting, said Martin Holst Lange, executive vice president for Development at Novo Nordisk. Todays results confirm the results from the previous reported ONWARDS trials and highlight that insulin icodec has the potential to be an ideal insulin for people with type 2 diabetes. We now look forward to sharing the results with regulatory authorities.
Novo Nordisk expects to file for regulatory approval of once-weekly insulin icodec in the US, the EU and China in the first half of 2023.
About the ONWARDS clinical development programme The ONWARDS programme for once-weekly insulin icodec currently comprises six phase 3a global clinical trials, including a trial with real-world elements, involving more than 4,000 adults with type 1 or type 2 diabetes.
ONWARDS 1 is a 78-week trial comparing the efficacy and safety of once-weekly insulin icodec with once-daily insulin glargine U100 both in combination with non-insulin anti-diabetic treatment in 984 insulin-nave people with type 2 diabetes. Following the completion of the main phase of the trial, a 26-week extension phase is ongoing. The results of the main phase were reported on 3 June 2022.
ONWARDS 2 was a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from a once-daily insulin. Results were reported on 28 April 2022.
ONWARDS 3 was a 26-week trial comparing once-weekly insulin icodec with once-daily insulin degludec. The objective of the trial was to assess the efficacy and safety of insulin icodec in 588 insulin-nave people with type 2 diabetes. Results were reported on 29 July 2022.
ONWARDS 4 was a 26-week trial comparing once-weekly insulin icodec with once-daily insulin glargine, both in combination with mealtime insulin. The objective of the trial was to assess the efficacy and safety of insulin icodec in 582 people with type 2 diabetes treated with basal and bolus insulin. Results were reported on 29 July 2022.
ONWARDS 5 was a 52-week trial comparing once-weekly insulin icodec with once-daily basal insulin (insulin degludec and insulin glargine U100 and U300) The objective of the trial was to assess the effectiveness and safety of insulin icodec, with an app providing dosing recommendation, in 1,085 insulin-nave people with type 2 diabetes in a clinical practice setting including no upper limit at HbA1c at time of inclusion, no limitations on use of oral antidiabetic treatments and fewer planned site visits compared to the other ONWARDS phase 3a trials (every third month in accordance with recommended clinical practice)
ONWARDS 6 is a 52-week trial comparing once-weekly insulin icodec with once-daily insulin degludec, both in combination with mealtime insulin. The objective of the trial is to assess the efficacy and safety of insulin icodec in 583 people with type 1 diabetes. Following the completion of the main phase of the trial, a 26-week extension phase is ongoing. The results of the main phase were reported on 3 June 2022.
About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisks B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Further information
Company announcement No 73 / 2022
See the rest here:
Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people...
- Virginia to offer diabetes-prevention classes - Essentia Health - March 1st, 2024
- Type 2 Diabetes: Red Light Therapy May Help Lower Blood Sugar - Healthline - March 1st, 2024
- Ultra-processed foods linked to over 30 health issues, from diabetes to heart trouble to cancer, research finds - CBS News - March 1st, 2024
- Mayo Clinic Minute: Expanding the living kidney donor pool to those with Type 2 diabetes - Mayo Clinic - March 1st, 2024
- Sugar tax shows sweet results in cutting obesity and diabetes rates - News-Medical.Net - March 1st, 2024
- What's the Connection Between Diabetes and Oral Health? - Medscape - March 1st, 2024
- ATTD 2024: Previewing the Latest on AID Systems, CGMs, and Diabetes Medications - diaTribe Foundation - March 1st, 2024
- What I Wish I Had Known When I Was Diagnosed with Type 2 Diabetes - EatingWell - March 1st, 2024
- Ultraprocessed foods linked to heart disease, diabetes, mental disorders and early death, study finds - CNN - March 1st, 2024
- Type 2 diabetes: Red light therapy could help lower blood sugar levels - Medical News Today - March 1st, 2024
- Unraveling the Link Between Type 2 Diabetes and Lower Back Pain: A New Frontier in Medical Research - Medriva - March 1st, 2024
- Scientists from 18 countries join forces to put end to 'pervasive, global problem' of diabetes stigma and discrimination - Medical Xpress - March 1st, 2024
- Bariatric surgery more effective than medical and lifestyle interventions for diabetes control and remission: Study - Medical Xpress - March 1st, 2024
- Unveiling Growth Prospects in the Type 2 Diabetes Industry: Major Drivers And Lucrative Segments As Per The ... - GlobeNewswire - March 1st, 2024
- Insulin-inhibitory receptor research offers hope for type 2 diabetes therapy - Medical Xpress - March 1st, 2024
- Over 4,800 persons with suspected symptoms of diabetes, hypertension identified during screening - The Hindu - March 1st, 2024
- Free cooking classes to be held in March to prevent Type 2 diabetes in Delco - The Delaware County Daily Times - March 1st, 2024
- Noblesville basketball's Aaron Fine hopes to inspire others with diabetes - IndyStar - March 1st, 2024
- One secret to preventing dementia, diabetes, and heart disease may lie in your oral health habits. Here's the dental ... - Fortune - March 1st, 2024
- Diabetes blood sugar reduction through new technology - The Jerusalem Post - March 1st, 2024
- More Funding to Reduce Costs, Improve Diabetes Care - Government of Nova Scotia - March 1st, 2024
- Many diagnosed with Type 2 diabetes may have a different form of the disease - NBC News - January 14th, 2024
- AI and the safe travel lane of diabetes care - Central Michigan University - January 14th, 2024
- Independent association of history of diabetic foot with all-cause mortality in patients with type 2 diabetes: the Renal ... - Cardiovascular... - January 14th, 2024
- Food an Effective Medicine in Diabetes? - Medscape - January 14th, 2024
- New insight into the pathogenesis of human diabetes - VA News - Veterans Affairs (.gov) - January 14th, 2024
- Controversy surrounding diabetes drug, Ozempic, being used tor weight loss - LiveNOW from FOX - January 14th, 2024
- Why are drugs that help battle obesity and diabetes so hard to get? - The Seattle Times - January 14th, 2024
- Semaglutide linked to lower suicidal ideation risk than other obesity, diabetes drugs - Healio - January 14th, 2024
- 5 "Bad" Carbs You Should Be Eating When You Have Diabetes, According to a Dietitian - EatingWell - January 14th, 2024
- 5 Breakfast Mistakes to Avoid If You Have Diabetes - EatingWell - January 14th, 2024
- Why don't fruit bats get diabetes? New understanding of how they've adapted to a high-sugar diet could lead to ... - The Conversation - January 14th, 2024
- OU professor discovers possible link between breast cancer drugs and Type 2 diabetes - KOCO Oklahoma City - January 14th, 2024
- Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 ... - PR Newswire - January 14th, 2024
- Loneliness Associated With Greater Burden of Care Among Caregivers of Children With Type 1 Diabetes - Drug Topics - January 14th, 2024
- Is Yogurt Good For Diabetes Or Not? A Review By Nutrition Professionals - MSN - January 14th, 2024
- Health Insurance Coverage and Costs for Type 1 Diabetes Screening - Beyond Type 1 - January 14th, 2024
- MCH to open free diabetes clinic thanks to $500,000 received from the City of Odessa - NewsWest9.com - January 14th, 2024
- Smart pens and insulin pump therapy for people with Type 2 diabetes - Omnia Health Insights - January 14th, 2024
- Tandem Diabetes Care's t:slim X2 Insulin Pump is the First Automated Insulin Delivery System to Integrate with ... - Yahoo Finance - January 14th, 2024
- Why fruit bats can eat tons of sugar without getting diabetes - Popular Science - January 14th, 2024
- Effect of Self-Care Activities and Behaviors on Glycemic Control in Patients With Diabetes at a Tertiary Care Hospital in ... - Cureus - January 14th, 2024
- This Is the Absolute Best Way To Stay Hydrated if You Have Diabetes - Northwest Georgia News - January 14th, 2024
- Artificial sweeteners dont aid weight loss, may increase diabetes, heart disease risk, says WHO - ThePrint - May 17th, 2023
- Diabetes: What It Is, Causes, Symptoms, Treatment & Types - April 23rd, 2023
- Medically supervised weight loss approach helps patients reduce risks of diabetes, heart disease and stroke - ABC4.com - April 23rd, 2023
- Dear Annie: Im worried about my sisters use of diabetes injections to drop a few pounds - OregonLive - February 6th, 2023
- Diabetes Drug Mounjaro Expected To Be Approved For Weight Loss Soon: What To Know And How It Compares To Similar Drugs - Forbes - February 6th, 2023
- Alcohol: Some People Have Higher Risk Of Heart Attack, Diabetes And Stroke More Than Binge Drinkers Signs Youre At Risk - Revyuh - February 6th, 2023
- Still Drinking Green Tea? Doctor Reveals A Healthier Drink With Proven Benefits For Diabetes, Aging, Oxidative Stress, And Cancer - Revyuh - January 4th, 2023
- How Cinnamon Lowers Blood Sugar and Fights Diabetes - Healthline - December 27th, 2022
- Diabetic Foot Ulcers: Causes and Treatments - Healthline - December 27th, 2022
- Diabetes: Are jaggery and honey healthier alternatives to sugar? Experts help you understand - Times of India - December 2nd, 2022
- Diabetes | Sutter Health - November 24th, 2022
- Effect of diet on type 2 diabetes mellitus: A review - PMC - November 24th, 2022
- Efficacy of Berberine in Patients with Type 2 Diabetes - PMC - November 24th, 2022
- First Drug to Delay Type 1 Diabetes Approved by FDA - Smithsonian Magazine - November 24th, 2022
- Learn how to prevent and manage diabetes - Lincoln Journal Star - October 29th, 2022
- Resilience may improve health among older adults with type 2 diabetes - Medical News Today - October 13th, 2022
- Years of Diabetes Could Speed Onset of Menopause | Health | derbyinformer.com - The Derby Informer - October 13th, 2022
- Insulin Use May Predict the Development of Diabetic Retinopathy - MD Magazine - October 13th, 2022
- The Most Crucial Eating Habit To Prevent Diabetes - Eat This, Not That - October 13th, 2022
- 2 Northeast Ohio teens born with type 1 diabetes deal with social anxieties of their condition at school - WKYC.com - October 13th, 2022
- University Hospitals nationally recognized for efforts to reduce uncontrolled blood pressure; address relationship between diabetes, heart disease,... - October 13th, 2022
- 5 Analysts Have This to Say About Tandem Diabetes Care - Tandem Diabetes Care (NASDAQ:TNDM) - Benzinga - October 13th, 2022
- Living with diabetes: Nutrition, exercise, routines, and more - Medical News Today - October 4th, 2022
- Cleveland Clinic - October 4th, 2022
- Researchers study long-term effectiveness of diabetes drugs - GW Hatchet - October 4th, 2022
- THE DIABETES LINK LAUNCHES TO HELP YOUNG ADULTS THRIVE WHILE LIVING WITH THE DISEASE - PR Newswire - October 4th, 2022
- Why people with diabetes have more UTIs and how to prevent infections - Medical News Today - October 4th, 2022
- Dealing With Type 1 Diabetes - Nick Jonas Behind New Men's Mental Health Initiative - Men's Health - October 4th, 2022
- Bionic pancreas improves type 1 diabetes management compared to standard insulin delivery methods - National Institutes of Health (.gov) - October 4th, 2022
- NOACs or Warfarin in Atrial Fibrillation With Diabetes - DocWire News - October 4th, 2022
- Why Type 1 Diabetes Is Tougher on Girls Than Boys - Healthline - October 4th, 2022
- Improve Diagnosis of Type of Heart Failure Common in Diabetes - Medscape - October 4th, 2022
- Insights on the Next Generation Diabetes Therapy and Drug Delivery Global Market to 2030 - Rising Incidences of Diabetes Globally and Increase in the... - October 4th, 2022
- Diabetes: TXNIP involved in increased secretion of glucagon from pancreatic alpha cells - University of Alabama at Birmingham - October 4th, 2022
- Peanut Butter and Diabetes: Can They Work Together? - Taste of Home - October 4th, 2022
- Prevalence of Microalbuminuria and Cardiovascular Risk Factors in Patients With Diabetes Mellitus Type-II in Al-Khobar, Kingdom of Saudi Arabia -... - October 4th, 2022
- Do Well, Be Well with Diabetes program starts Oct. 6 in Waco - AgriLife Today - September 25th, 2022